Physician profile
Marc Hull
NPI 1326195876
$690.33
in general payments reported to CMS, 2019-2025
22 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.08 · 2024: $320 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $95.22 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $63.90 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $61.43 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $49.69 | 2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.50 | 2024-2025 | Xifaxan |
| Alk-Abello, INC | $38.50 | 2024-2025 | Grastek, Ragwitek, Odactra |
| Exact Sciences Corporation | $37.09 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $35.69 | 2024-2025 | Gemtesa |
| Shield Therapeutics INC | $28.82 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.56 | 2024 | |
| Genentech USA, INC. | $23.08 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.26 | 2024 | Spravato |
| Seqirus USA INC | $19.39 | 2024 | Fluad, Flucelvax |
| Abbott Laboratories | $18.12 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $17.96 | 2024 | Airsupra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $16.67 | 2024 | Intellis Adaptivestim |
| Amgen INC. | $16.35 | 2024 | Enbrel |
| Novo Nordisk INC | $16.34 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.90 | 2024 | |
| Corcept Therapeutics | $15.65 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $15.02 | 2025 | Sunosi |
| Ascensia Diabetes Care US INC. | $14.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.